ofloxacin has been researched along with Skin Diseases, Bacterial in 22 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Skin Diseases, Bacterial: Skin diseases caused by bacteria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 9.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 6.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 5.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| " This pharmacokinetic modeling could be used to determine optimal treatment dose in clinical trials in a shorter time frame with fewer patients." | 2.69 | Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. ( Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V, 1998) |
| " Drug-related adverse events were reported by 8." | 2.69 | A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. ( Jasovich, A; Neto, W; Nicodemo, AC; Robledo, JA, 1998) |
| "Levofloxacin is a second generation fluoroquinolone with a post marketing history of well tolerated and successful use in a variety of clinical situations." | 2.41 | A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. ( Garvin, CG; Jung, R; Martin, SJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 2 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dabas, G | 1 |
| Sharma, K | 1 |
| Narang, T | 1 |
| Sharma, M | 1 |
| Chatterjee, D | 1 |
| Dogra, S | 1 |
| Blatun, LA | 2 |
| Terekhova, RP | 1 |
| Ota, R | 1 |
| Iwasawa, MT | 1 |
| Ohkusu, K | 1 |
| Kambe, N | 1 |
| Matsue, H | 1 |
| Fujita, N | 1 |
| Utani, A | 1 |
| Matsumoto, F | 1 |
| Matsushima, H | 1 |
| Kakuta, M | 1 |
| Hatamochi, A | 1 |
| Shinkai, H | 1 |
| Bormann, G | 1 |
| Marsch, WC | 1 |
| Iakovlev, VP | 1 |
| Svetukhin, AM | 1 |
| Ukhin, SA | 1 |
| Nakagawa, K | 1 |
| Tsuruta, D | 1 |
| Ishii, M | 1 |
| Valero, G | 1 |
| Moreno, F | 1 |
| Graybill, JR | 1 |
| Gentry, LO | 1 |
| Rodriguez-Gomez, G | 1 |
| Liu, HH | 1 |
| Bolash, NK | 1 |
| McAnany, ME | 1 |
| Lynch, RA | 1 |
| Iijima, S | 1 |
| Saito, J | 1 |
| Otsuka, F | 1 |
| Preston, SL | 1 |
| Drusano, GL | 1 |
| Berman, AL | 1 |
| Fowler, CL | 1 |
| Chow, AT | 1 |
| Dornseif, B | 1 |
| Reichl, V | 1 |
| Natarajan, J | 1 |
| Corrado, M | 1 |
| Nicodemo, AC | 1 |
| Robledo, JA | 1 |
| Jasovich, A | 1 |
| Neto, W | 1 |
| Akiyama, H | 1 |
| Yamasaki, O | 1 |
| Kanzaki, H | 1 |
| Tada, J | 1 |
| Arata, J | 1 |
| Fridolijn Jongevos, S | 1 |
| Prens, EP | 1 |
| Habets, JM | 1 |
| de Jong, JJ | 1 |
| van Gelder, T | 1 |
| IJzermans, JN | 1 |
| Endtz, HP | 1 |
| Weimar, W | 1 |
| Trampuz, A | 1 |
| Wenk, M | 1 |
| Rajacic, Z | 1 |
| Zimmerli, W | 1 |
| Hooper, DC | 1 |
| Del Pozo, JL | 1 |
| Lecároz, C | 1 |
| Hernáez, S | 1 |
| Leiva, J | 1 |
| Ballester, B | 1 |
| Martin, SJ | 1 |
| Jung, R | 1 |
| Garvin, CG | 1 |
| Tarshis, GA | 1 |
| Miskin, BM | 1 |
| Jones, TM | 1 |
| Champlin, J | 1 |
| Wingert, KJ | 1 |
| Breen, JD | 1 |
| Brown, MJ | 1 |
| Blondeau, JM | 1 |
5 reviews available for ofloxacin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
[Levofloxacin in complex therapy of patients with skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Humans; Levofloxacin; Ofloxacin; Skin Diseases, Bacterial; Soft Tissue Infect | 2008 |
[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Ciprofloxacin; Gastro | 2004 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Pi | 2000 |
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Microbial; Drug-Related Side Effects and Adverse Re | 2001 |
The role of fluoroquinolones in skin and skin structure infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Micr | 2002 |
5 trials available for ofloxacin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Ofloxacin treatment of difficult infections of the skin and skin structure.
Topics: Abscess; Administration, Oral; Adult; Aged; Aged, 80 and over; Cellulitis; Drug Administration Sched | 1993 |
Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin.
Topics: Adolescent; Adult; Anti-Infective Agents; Bacteria; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug | 1995 |
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
Topics: Adult; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Bayes Theorem; Dose-Response R | 1998 |
A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Female; Huma | 1998 |
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Admi | 2001 |
12 other studies available for ofloxacin and Skin Diseases, Bacterial
| Article | Year |
|---|---|
Cutaneous non-tubercular mycobacterial infection in pregnancy and treatment consideration.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Linezolid; Mycobacterium fortuitum; Mycobacterium Infe | 2019 |
Maximum growth temperature test for cutaneous Mycobacterium chelonae predicts the efficacy of thermal therapy.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Hyperthermia, In | 2012 |
Levofloxacin alone efficiently treated a cutaneous mycobacterium fortuitum infection.
Topics: Administration, Oral; Adolescent; Anti-Infective Agents; Drug Administration Schedule; Female; Follo | 2002 |
[Sporotrichoid atypical mycobacterial infections. Antibiotic monotherapy].
Topics: Adult; Biopsy; Clarithromycin; Diagnosis, Differential; Drug Resistance, Multiple, Bacterial; Female | 2004 |
Successful treatment of a widespread cutaneous Mycobacterium fortuitum infection with levofloxacin.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Levofloxacin; Mycobacterium; Mycobacterium fortuitum; | 2006 |
Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection.
Topics: Animals; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Male; Mice; | 1994 |
Mycobacterium marinum skin infection successfully treated with levofloxacin.
Topics: Adult; Anti-Infective Agents; Humans; Levofloxacin; Male; Mycobacterium Infections, Nontuberculous; | 1997 |
Streptococci isolated from various skin lesions: the interaction with Staphylococcus aureus strains.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Erythromycin; Fluoroquinol | 1999 |
Successful triple-antibiotic therapy for cutaneous infection due to Mycobacterium chelonae.
Topics: Aged; Doxycycline; Drug Therapy, Combination; Ethambutol; Female; Humans; Mycobacterium chelonae; My | 1999 |
Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient.
Topics: Clarithromycin; Drug Therapy, Combination; Ethambutol; Foot; Humans; Kidney Transplantation; Male; M | 1999 |
Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
Topics: Anti-Infective Agents; Blister; Body Fluids; Granulocytes; Humans; Levofloxacin; Microbial Sensitivi | 2000 |
[Recurrent abscesses in a renal transplant recipient].
Topics: Abscess; Drug Therapy, Combination; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney | 2001 |